Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/229
Title: | Representativeness of Honeypot Trial Participants to Australasian PD Patients | Authors: | McTaggart, S. Committee, Honeypot Trial Writing Isbel, N. M. Group, Honeypot Study Collaborative Snelling, P. Badve, S. V. Playford, G. Scaria, A. Beller, E. Cass, A. Zhang, L. de Zoysa, J. Vergara, L. A. Morrish, A. T. Clark, C. Liu, X. Pascoe, E. M. Johnson, D. W. Hawley, C. M. |
Issue Date: | 2017 | Source: | 37, (5), 2017, p. 516-522 | Pages: | 516-522 | Journal: | Peritoneal Dialysis International | Abstract: | BACKGROUND: The HONEYPOT trial failed to establish the superiority of exit-site application of Medihoney compared with nasal mupirocin prophylaxis for the prevention of peritonitis in peritoneal dialysis (PD) patients. This study aimed to assess the representativeness of the patients in the HONEYPOT trial to the Australian and New Zealand PD population.METHODS: This study compared baseline characteristics of the 371 PD patients in the HONEYPOT trial with those of 6,085 PD patients recorded on the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. | DOI: | 1256 | Resources: | http://scproxy.slq.qld.gov.au/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=27935534http://linksource.ebsco.com/athens.b6e6cc08-c492-42af-aec4-c6084e18e68c/linking.aspx?sid=OVID:medline&id=pmid:27935534&id=doi:10.3747%2Fpdi.2016.00065&issn=0896-8608&isbn=&volume=37&issue=5&spage=516&date=2017&title=Peritoneal+Dialysis+International&atitle=Representativeness+of+Honeypot+Trial+Participants+to+Australasian+PD+Patients.&aulast=Zhang&pid=%3CAN%3E27935534%3C%2FAN%3E | Type: | Article |
Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.